Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + gemcitabine + docetaxel
- Development stage
- Unknown
- Lead developer
- Ruijin Hospital
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
The designation GD-Ruijin Hospital-osteosarcoma refers to a combination chemotherapy and targeted therapy regimen being evaluated in the Phase II PROACH trial (NCT03742193) at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. This regimen consists of the small molecule tyrosine kinase inhibitor apatinib combined with the chemotherapy drugs gemcitabine and docetaxel (GD). Apatinib selectively targets vascular endothelial growth factor receptor-2 (VEGFR-2) to inhibit tumor angiogenesis. Gemcitabine is a pyrimidine nucleoside analog that inhibits DNA synthesis, while docetaxel is a taxane that promotes microtubule assembly and stabilization, leading to cell cycle arrest. The regimen is specifically studied for the treatment of resectable pulmonary metastases in patients with osteosarcoma, typically administered as perioperative therapy followed by apatinib maintenance monotherapy.
- Other names
- apatinib + gemcitabine + docetaxelGD + apatinibapatinib + GD
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNAVEGFR2 (Vascular endothelial growth factor receptor 2)ABCB1 (P-glycoprotein)
Beyond the preview
Go deeper on apatinib + gemcitabine + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + gemcitabine + docetaxel.